| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CCR1 |
| Uniprot No | P32246 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-355aa |
| 氨基酸序列 | METPNTTEDYDTTTEFDYGDATPCQKVNERAFGAQLLPPLYSLVFVIGLVGNILVVLVLVQYKRLKNMTSIYLLNLAISDLLFLFTLPFWIDYKLKDDWVFGDAMCKILSGFYYTGLYSEIFFIILLTIDRYLAIVHAVFALRARTVTFGVITSIIIWALAILASMPGLYFSKTQWEFTHHTCSLHFPHESLREWKLFQALKLNLFGLVLPLLVMIICYTGIIKILLRRPNEKKSKAVRLIFVIMIIFFLFWTPYNLTILISVFQDFLFTHECEQSRHLDLAVQVTEVIAYTHCCVNPVIYAFVGERFRKYLRQLFHRRVAVHLVKWLPFLSVDRLERVSSTSPSTGEHELSAGF |
| 预测分子量 | 42.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CCR1重组蛋白的3篇代表性文献示例(内容为模拟概括，建议通过学术数据库核实最新研究)：
---
1. **标题**: "Expression and functional characterization of recombinant human CCR1 in insect cells"
**作者**: Smith A, et al.
**摘要**: 研究利用杆状病毒-昆虫细胞系统表达人源CCR1重组蛋白，通过亲和层析纯化获得高纯度蛋白。实验证实重组CCR1能结合趋化因子MIP-1α并激活下游G蛋白信号通路，为受体功能研究提供工具。
2. **标题**: "Structural insights into CCR1 activation by chemokine ligands"
**作者**: Zhang Y, et al.
**摘要**: 通过哺乳动物细胞表达系统制备CCR1重组蛋白，结合冷冻电镜技术解析其与配体CCL3的复合物结构，揭示了跨膜结构域构象变化对受体激活的关键作用，为靶向药物设计提供结构基础。
3. **标题**: "Development of a CCR1 recombinant cell line for high-throughput antagonist screening"
**作者**: Lee H, et al.
**摘要**: 构建稳定表达CCR1重组蛋白的HEK293细胞系，结合钙流检测和β-arrestin招募实验建立高通量筛选平台，成功鉴定出新型小分子拮抗剂，可用于炎症性疾病药物开发。
---
**检索建议**：
可通过PubMed或Google Scholar搜索关键词：
- "CCR1 recombinant protein expression"
- "CCR1 structure-function analysis"
- "CCR1 antagonist screening"
筛选近5年文献以获取最新进展。
CCR1 (C-C chemokine receptor type 1) is a G protein-coupled receptor (GPCR) that plays a pivotal role in immune regulation and inflammatory responses. It belongs to the chemokine receptor family and primarily binds to C-C motif ligands such as CCL3 (MIP-1α), CCL5 (RANTES), and CCL7 (MCP-3). Expressed on various immune cells, including monocytes, neutrophils, T cells, and dendritic cells, CCR1 mediates chemotaxis and cellular activation in response to inflammatory signals. Its activation triggers intracellular signaling pathways, such as calcium mobilization and MAP kinase activation, which are critical for leukocyte recruitment to infection or injury sites.
Recombinant CCR1 protein is engineered for in vitro studies to elucidate its structural and functional properties. Produced using heterologous expression systems (e.g., mammalian, insect, or bacterial cells), the recombinant form typically retains key domains, such as the seven transmembrane helices and ligand-binding regions, enabling interaction studies with chemokines or potential therapeutic inhibitors. Purification tags (e.g., His-tag) are often incorporated to facilitate isolation and characterization.
Research on recombinant CCR1 is driven by its implication in chronic inflammatory diseases (e.g., rheumatoid arthritis, multiple sclerosis) and cancer metastasis. It serves as a target for drug discovery, with efforts focused on developing antagonists to block pathogenic leukocyte migration. Additionally, recombinant CCR1 is used in ligand-receptor binding assays, signaling pathway analysis, and high-throughput screening platforms. Challenges remain in maintaining its native conformation and post-translational modifications during production, which are essential for functional studies. Understanding CCR1's role through recombinant models continues to advance therapeutic strategies for immune-related disorders.
×
